On February 17, 2022, Bushaboina, Mallesh; Chen, Xin; Cheung, Atwood Kim; Culshaw, Andrew James; Hurley, Timothy Brian; Labbe-Giguere, Nancy; Miltz, Wolfgang; Orain, David; Patel, Tajesh; Rajagopalan, Srinivasan; Roehn, Till; Sandham, David Andrew; Thoma, Gebhard; Tichkule, Ritesh Bhanudasji; Waelchli, Rudolf published a patent.Recommanded Product: 87486-34-8 The title of the patent was Preparation of heteroaryl substituted spiropiperidinyl derivatives as LTC4S inhibitors and pharmaceutical uses thereof. And the patent contained the following:
The invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The invention further provides a combination of pharmacol. active agents and a pharmaceutical composition Compounds of formula I wherein R1 is (un)substituted phenyl; R2 is H and F; X1 is CH2 and O; R4 is (un)substituted (mono/bi)cyclic heteroaryl; and a pharmaceutically acceptable salt thereof, are claimed. Example compound II was prepared by oxidation of 2-(4-fluorophenyl)-1-hydrazinecarbothiomide; the resulting (E)-amino(2-(4-fluorophenyl)hydrazono)methanesulfonic acid underwent amination with 1-(4-chloro-3-fluorophenyl)-1,9-diazaspiro[5.5]undecane-2-one to give 1-(4-chloro-3-fluorophenyl)-N’-(4-fluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecane-9-carboximidehydrazide, which underwent cyclization to give compound II. The invention compounds were evaluated for their LTC4S inhibitory activity (data given). The experimental process involved the reaction of 3,5-Dibromo-1-methylpyrazin-2(1H)-one(cas: 87486-34-8).Recommanded Product: 87486-34-8
The Article related to heteroaryl spiropiperidine preparation ltc4s inhibitor, Heterocyclic Compounds (One Hetero Atom): Spiro Compounds With One Hetero Atom In Each Ring and other aspects.Recommanded Product: 87486-34-8